TY - JOUR
T1 - Arthrofibrosis Nightmares
T2 - Prevention and Management Strategies
AU - Lee, Dustin R.
AU - Therrien, Erik
AU - Song, Bryant M.
AU - Camp, Christopher L.
AU - Krych, Aaron J.
AU - Stuart, Michael J.
AU - Abdel, Matthew P.
AU - Levy, Bruce A.
N1 - Funding Information:
This study was partially funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for the Musculoskeletal Research Training Program (T32AR56950). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Funding Information:
This study was partially funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for the Musculoskeletal Research Training Program (T32AR56950). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Funding Information:
Disclosure: C.L.C. reports personal fees and nonfinancial support from Arthrex, nonfinancial support from Zimmer Biomet, nonfinancial support from Stryker Corporation. A.J.K. reports grants from Aesculap/B.Braun, other from American Journal of Sports Medicine, personal fees and other from Arthrex Inc., grants from Arthritis foundation, grants from Ceterix, grants from Histogenics, other from International Cartilage Repair Society, other from International society of Arthroscopy, Knee surgery, and orthopaedic sports medicine, other from Minnesota Orthopedic society, personal fees and other from Musculoskeletal Transplant Foundation, personal fees from Vericel, personal fees from DePuy, personal fees from JRF, grants from Exactech, grants from Gemini Medical, personal fees from Responsive Arthroscopy. M.J.S. reports involvement in the editorial or governing board for the American Journal of Sports Medicine, grants and personal fees from Arthrex Inc., grants from Stryker. M.P.A. reports involvement in the board or committee member of AAOS, publishing royalties, financial or material support from Springer, and IP royalties from Stryker. B.A.L. reports personal fees from Arthrex Inc.: IP royalties; Paid consultant, grants from Biomet: Research support, editorial or governing board for Clinical Orthopaedics and Related Research, Journal of Knee Surgery, Knee Surgery, Sports Traumatology, Arthroscopy, Orthopedics Today; grants and personal fees from Smith & Nephew: Paid consultant; Research support, grants from Stryker: Research support, personal fees from Linvatec: Faculty/speaker, personal fees from COVR Medical LLC. The remaining authors declare no conflict of interest.
Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Arthrofibrosis (AF) is an exaggerated immune response to a proinflammatory insult leading to pathologic periarticular fibrosis and symptomatic joint stiffness. The knee, elbow, and shoulder are particularly susceptible to AF, often in the setting of trauma, surgery, or adhesive capsulitis. Prevention through early physiotherapeutic interventions and anti-inflammatory medications remain fundamental to avoiding motion loss. Reliable nonoperative modalities exist and outcomes are improved when etiology, joint involved, and level of dysfunction are considered in the clinical decision making process. Surgical procedures should be reserved for cases recalcitrant to nonoperative measures. The purpose of this review is to provide an overview of the current understanding of AF pathophysiology, identify common risk factors, describe prevention strategies, and outline both nonoperative and surgical treatment options. This manuscript will focus specifically on sterile AF of the knee, elbow, and shoulder.
AB - Arthrofibrosis (AF) is an exaggerated immune response to a proinflammatory insult leading to pathologic periarticular fibrosis and symptomatic joint stiffness. The knee, elbow, and shoulder are particularly susceptible to AF, often in the setting of trauma, surgery, or adhesive capsulitis. Prevention through early physiotherapeutic interventions and anti-inflammatory medications remain fundamental to avoiding motion loss. Reliable nonoperative modalities exist and outcomes are improved when etiology, joint involved, and level of dysfunction are considered in the clinical decision making process. Surgical procedures should be reserved for cases recalcitrant to nonoperative measures. The purpose of this review is to provide an overview of the current understanding of AF pathophysiology, identify common risk factors, describe prevention strategies, and outline both nonoperative and surgical treatment options. This manuscript will focus specifically on sterile AF of the knee, elbow, and shoulder.
KW - Arthrofibrosis prevention/treatment
KW - Elbow
KW - Knee
KW - Lyses of adhesions
KW - Manipulation under anesthesia
KW - Shoulder
UR - http://www.scopus.com/inward/record.url?scp=85123973938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123973938&partnerID=8YFLogxK
U2 - 10.1097/JSA.0000000000000324
DO - 10.1097/JSA.0000000000000324
M3 - Review article
C2 - 35113841
AN - SCOPUS:85123973938
VL - 30
SP - 29
EP - 41
JO - Sports Medicine and Arthroscopy Review
JF - Sports Medicine and Arthroscopy Review
SN - 1062-8592
IS - 1
ER -